Must of had his eye glasses blurred during the making of this slide. I dare Dr M present an efficacy slide like this before a multi thousand patient, multiple year ph 3 trial! It just doesnt happen folks.....or does it?
So think about the 43 subjects taking 50 mg per day in the Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia who achieved an average improvement of 2 point over the baseline and 4 point improvement over the placebo cohort at 14 weeks into the trial.
Click on the image below:
Imagine the the additional improvement after 52 weeks on the Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001.
News 
Market Data 
Discover 
